A Comprehensive Monograph on Defibrotide (DB04932)

Executive Summary

Defibrotide represents a unique therapeutic agent in modern medicine, distinguished by its singular role as the only approved treatment for a rare, fulminant, and often fatal complication of hematopoietic stem-cell transplantation (HSCT). Marketed under the brand name Defitelio®, Defibrotide is a complex biologic drug, comprising a purified mixture of single-stranded polydeoxyribonucleotides derived from porcine intestinal mucosa.[1] Its sole indication is for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), accompanied by renal or pulmonary dysfunction.[3] This condition, which arises from endothelial damage caused by high-dose conditioning chemotherapy, carries a mortality rate exceeding 80% when left untreated.[1]

The mechanism of action of Defibrotide, while not fully elucidated, is understood to be pleiotropic, centered on the protection of vascular endothelial cells and the restoration of local thrombo-fibrinolytic balance in the hepatic microvasculature.[1] It exerts profibrinolytic, antithrombotic, and anti-inflammatory effects, primarily by modulating key regulatory proteins on the endothelial surface without inducing significant systemic anticoagulation.[2] The clinical efficacy of Defibrotide was established through a series of studies, including a pivotal Phase 3 trial that demonstrated a statistically significant improvement in Day +100 survival rates compared to meticulously selected historical controls.[6] This evidence base, while unconventional, was deemed sufficient for regulatory approval given the extreme lethality of the disease and the ethical impossibility of conducting a placebo-controlled trial.

The principal and most significant safety concern associated with Defibrotide therapy is the risk of hemorrhage.[1] This risk necessitates careful patient selection, vigilant monitoring, and strict contraindication of concurrent systemic anticoagulant or fibrinolytic therapies.[3] The regulatory journey of Defibrotide in both the United States and the European Union serves as a compelling case study in pragmatic drug regulation for orphan diseases. Its approval was facilitated by multiple expedited pathways, including Orphan Drug Designation, Priority Review, and an "exceptional circumstances" authorization, reflecting a flexible, risk-based approach to addressing urgent and unmet medical needs.[5] Defibrotide thus occupies a paradoxical position: it is an indispensable, life-saving agent whose compelling clinical outcomes have outpaced a complete molecular characterization of its function, highlighting a scenario where the magnitude of clinical benefit in a desperate situation has driven therapeutic advancement.

Drug Identification and Physicochemical Properties

A precise understanding of Defibrotide's identity and composition is fundamental to appreciating its unique pharmacological profile and clinical application. As a biologic agent derived from a natural source, its characteristics differ substantially from those of synthetic small-molecule drugs.

Nomenclature and Identifiers

Defibrotide is recognized globally by a consistent set of names and registry numbers that ensure accurate identification across clinical, research, and regulatory domains.

• Generic Name: Defibrotide; Defibrotide Sodium [2]
• Brand Names: The primary global brand name is Defitelio®.[1] Other historical or regional brand names include Noravid and Prociclide.[15]
• Registry Numbers:
• CAS Number: 83712-60-1 [2]
• DrugBank ID: DB04932 [1]
• FDA UNII (Unique Ingredient Identifier): 568FY5I1YI (for Defibrotide free acid); L7CHH2B2J0 (for Defibrotide Sodium) [2]
• Drug Class: Defibrotide is classified as a miscellaneous coagulation modifier and an antithrombotic agent.[3] Within the Anatomical Therapeutic Chemical (ATC) classification system, its code is B01AX01.[15] It is fundamentally a biotech product and is categorized as a nucleic acid-based therapy.[17]

Chemical and Biological Profile

The defining feature of Defibrotide is that it is not a single chemical entity but a complex biological mixture. This characteristic is the source of both its therapeutic activity and some of its clinical challenges.

• Description and Source: Defibrotide is a purified mixture of predominantly single-stranded polydeoxyribonucleotides, formulated as a sodium salt.[1] It is produced via a process of controlled depolymerization of deoxyribonucleic acid (DNA) extracted from the intestinal mucosa of pigs (porcine origin).[1] This biological origin is critical, as it explains the polydisperse nature of the final drug product and the inherent risk of immunogenicity.
• Physicochemical Characteristics:
• Molecular Composition: As a polydisperse mixture of oligonucleotides of varying lengths and sequences, Defibrotide does not have a single molecular formula or weight. The average molecular weight of the constituent molecules falls within a range of 13,000 to 20,000 Daltons (13-20 kDa).[18] Certain databases may list a specific molecular formula (e.g., C20H21N4O6P) or a corresponding weight, but these represent a single, illustrative nucleotide fragment and are not representative of the drug product as a whole.[8]
• Formulation and Presentation: Defibrotide is supplied as a sterile, preservative-free, clear, colorless to light yellow concentrate for solution for infusion. It is provided in single-use glass vials containing 200 mg of Defibrotide in 2.5 mL of solution, yielding a concentration of 80 mg/mL.[19]
• Storage and Stability: Unopened vials are to be stored at temperatures below 25°C and must not be frozen. After dilution with a compatible solution (e.g., 0.9% Sodium Chloride or 5% Dextrose), chemical and physical in-use stability has been demonstrated for up to 72 hours at room temperature. However, from a microbiological perspective, immediate use after preparation is strongly recommended. If immediate use is not possible, storage should not exceed 24 hours under refrigeration (2-8°C).[21]

The biological and complex nature of Defibrotide is directly linked to several of its most important clinical features. Because it is a mixture of many different oligonucleotides, it is difficult to attribute its therapeutic effect to a single molecular target or pathway, leading to the description of a multifactorial or "pleiotropic" mechanism of action. Furthermore, its derivation from a non-human animal source introduces foreign biological material into the patient, creating an intrinsic potential for immunologic reactions, which manifests clinically as the observed risk of hypersensitivity and anaphylaxis.[1] Finally, as a biologic therapeutic, it is more fragile than a small molecule and requires specific handling protocols, including careful dilution, administration through a filter, and strict aseptic technique, to ensure its integrity and safe delivery to the patient.[9]

Comprehensive Pharmacological Profile

The pharmacology of Defibrotide is complex and not yet fully defined. However, extensive in vitro and clinical research has illuminated a multifactorial mechanism centered on endothelial protection and the modulation of hemostasis, which collectively explains its efficacy in the treatment of VOD/SOS.

Mechanism of Action

The therapeutic effect of Defibrotide is not attributable to a single pathway but rather to a convergence of several biological activities that counteract the core pathology of VOD/SOS.

• Profibrinolytic and Antithrombotic Effects: The primary pathology of VOD/SOS is microthrombosis within the hepatic sinusoids, driven by a shift towards a prothrombotic state. Defibrotide acts to reverse this imbalance. In vitro studies demonstrate that it enhances the enzymatic activity of plasmin, the body's primary clot-dissolving enzyme, to hydrolyze fibrin clots.[7] It achieves this by modulating the expression of key regulatory proteins on the surface of endothelial cells. Specifically, it increases the expression of tissue plasminogen activator (t-PA), which converts plasminogen to plasmin, and thrombomodulin, which is involved in downregulating coagulation. Concurrently, it decreases the expression of plasminogen activator inhibitor-1 (PAI-1), a primary inhibitor of t-PA, and von Willebrand factor (vWF), a protein critical for platelet adhesion and aggregation.[1] The net effect is a restoration of the local thrombo-fibrinolytic homeostasis at the site of endothelial injury. A crucial feature of this activity is that it occurs without causing significant systemic anticoagulation, distinguishing Defibrotide from agents like heparin and reducing the risk of spontaneous systemic bleeding compared to traditional anticoagulants.[2]
• Endothelial Cell Protection: The initial insult in VOD/SOS is damage to the sinusoidal endothelial cells by high-dose chemotherapy.[5] Defibrotide has demonstrated a direct cytoprotective effect on these cells. In vitro experiments have shown that it can protect endothelial cells from damage induced by various stressors, including chemotherapy drugs like fludarabine, inflammatory cytokines such as tumor necrosis factor-α (TNF-α), and serum starvation.[1] This protective action may help to limit ongoing damage and facilitate the recovery of the microvascular architecture of the liver.
• Anti-inflammatory and Anti-ischemic Properties: Defibrotide also appears to possess broader anti-inflammatory and vasodilatory properties. Evidence suggests it stimulates the release of endogenous prostaglandins, particularly prostacyclin (PGI2) and prostaglandin E2 (PGE2).[2] PGI2 is a potent vasodilator and inhibitor of platelet aggregation, which would help to improve blood flow and reduce thrombosis in the occluded sinusoids.[2] Additionally, Defibrotide may function as an agonist at adenosine receptors (A1, A2a, and A2b), which are known to play roles in modulating inflammation, vascular tone, and ischemic injury.[17]

Pharmacodynamics

The pharmacodynamic profile of Defibrotide relates its concentration in the body to its clinical effects. A Phase 2 dose-finding trial was instrumental in establishing the currently recommended dose. This study compared two dosing regimens, 6.25 mg/kg every 6 hours (total daily dose of 25 mg/kg) and 10 mg/kg every 6 hours (total daily dose of 40 mg/kg). The results showed no meaningful difference in either the complete response rate or the Day +100 survival rate between the two arms. However, a slightly higher incidence of treatment-related adverse events was noted at the higher dose, leading to the selection of the 25 mg/kg/day regimen as the optimal balance of efficacy and safety for pivotal trials and clinical use.[7]

Attempts to identify a reliable pharmacodynamic biomarker to monitor Defibrotide's activity have been challenging. Plasma levels of PAI-1 were investigated as a potential marker of the drug's profibrinolytic effect. While PAI-1 levels tended to be lower in patients who achieved a complete response or were alive at Day +100, this trend did not reach statistical significance, and no clear dose-response relationship was established.[9] In terms of cardiac safety, a thorough QT study demonstrated that at doses up to 2.4 times the maximum recommended therapeutic dose, Defibrotide does not prolong the QTc interval to any clinically relevant extent.[9]

Pharmacokinetics (ADME Profile)

The pharmacokinetic profile of Defibrotide is characterized by its intravenous administration, high protein binding, and rapid elimination.

• Absorption: As an intravenously administered drug, Defibrotide has 100% bioavailability. Peak plasma concentrations are typically observed at the conclusion of the 2-hour infusion period.[9] While an oral formulation has been studied and demonstrates 58-70% bioavailability, this route is not used for the approved indication.[2]
• Distribution: Defibrotide is highly bound to human plasma proteins, with an average binding of approximately 93%. It has a relatively small volume of distribution, ranging from 8.1 to 9.1 L, suggesting it is primarily confined to the vascular compartment.[7]
• Metabolism: The precise metabolic fate of Defibrotide in humans is not fully known. As a complex of polynucleotides, it is presumed to be progressively degraded by endogenous enzymes. This process likely involves plasma exonucleases, which break it down into smaller oligonucleotides, followed by further metabolism by nucleotidases and other enzymes into its constituent nucleosides, free purine and pyrimidine bases, and 2'-deoxyribose sugars.[7] In vitro studies using human hepatocytes have shown that Defibrotide does not undergo appreciable metabolism by these cells, suggesting that its clearance is not primarily dependent on hepatic enzyme systems like the cytochrome P450 pathway.[7]
• Elimination: The primary route of elimination is metabolism, followed by the renal excretion of the resulting metabolites. Only a small fraction of the administered dose, approximately 5-15%, is excreted unchanged in the urine, with the majority of this occurring within the first 4 hours after infusion.[7] Defibrotide has a very short terminal half-life, which is consistently less than 2 hours. This rapid clearance means that the drug does not accumulate in the plasma with the recommended every-6-hour dosing regimen.[7]
• Pharmacokinetics in Special Populations: The pharmacokinetics of Defibrotide have been studied in patients with renal impairment. In individuals with severe renal impairment or end-stage renal disease (ESRD), drug exposure (as measured by AUC) is approximately 50-60% higher, and peak concentrations (Cmax) are about 35-37% higher compared to healthy subjects. Despite this increased exposure, the terminal half-life remains short (<2 hours), and the drug is not removed by hemodialysis. Consequently, no dose adjustment is recommended for patients with renal impairment.[7] Similarly, no dose adjustments are required based on age (for patients over one month old) or for hepatic impairment.[7]

The integrated pharmacological profile of Defibrotide reveals a fascinating dichotomy that defines its clinical use. Its mechanism of action appears to be primarily localized to the site of injury—the damaged vascular endothelium of the hepatic sinusoids—where it works to restore normal function. This is supported by its ability to modulate endothelial surface proteins and the observation that it lacks significant systemic anticoagulant properties.[2] However, its primary safety liability, the risk of hemorrhage, is systemic. This creates a clinical paradigm where a drug is used to treat a localized liver pathology, but its use requires vigilant management of a systemic bleeding risk. The very short half-life of Defibrotide is a critical mitigating factor in this paradigm; its profibrinolytic effect dissipates quickly after the infusion is stopped, allowing for more dynamic management of bleeding events or preparation for necessary invasive procedures.[7]

Clinical Efficacy and Medical Applications

The clinical development and approval of Defibrotide were driven by the urgent need for an effective therapy for severe hepatic VOD/SOS, a condition with an exceptionally high mortality rate for which no approved treatments existed. The evidence supporting its use is a testament to a pragmatic approach to drug evaluation in the context of a life-threatening orphan disease.

Approved Indication: Treatment of Severe Hepatic Veno-Occlusive Disease (VOD/SOS)

Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved Defibrotide for a specific and well-defined patient population. The indication is for the treatment of adult and pediatric patients (including infants over one month of age) with hepatic VOD/SOS who have evidence of renal or pulmonary dysfunction following HSCT.[3]

VOD/SOS is a severe and potentially lethal complication that arises from the high-dose cytotoxic conditioning regimens administered to patients prior to HSCT. This therapy causes profound damage to the sinusoidal endothelial cells of the liver, leading to a clinical syndrome characterized by the obstruction of hepatic sinusoids and small intrahepatic veins. The clinical manifestations include painful hepatomegaly, jaundice (hyperbilirubinemia), and significant fluid retention leading to ascites and weight gain.[1] In its most severe form, the condition progresses to multi-organ failure, typically involving the kidneys and lungs. Untreated severe VOD/SOS is associated with a mortality rate of 80% to 84%.[1] Prior to the approval of Defibrotide, management was limited to supportive care, and no other therapy had demonstrated a survival benefit. Defibrotide remains the first and only approved treatment for this devastating condition.[24]

Pivotal Clinical Trials and Supporting Evidence for Treatment

The regulatory approvals of Defibrotide were granted based on a comprehensive data package derived from three key studies, which collectively included 528 patients with diagnosed severe VOD/SOS.[4] Due to the high mortality of the disease, a randomized, placebo-controlled trial was deemed ethically and logistically infeasible. Therefore, the pivotal evidence was generated using a historically controlled study design, supplemented by data from a second prospective trial and a large expanded access program.

The cornerstone of the evidence is the pivotal Phase 3 trial (NCT00358501). This was a multicenter, open-label study that prospectively treated 102 adult and pediatric patients who had severe VOD with multi-organ failure following HSCT.[6] The outcomes for these patients were compared to a contemporaneous historical control group. This control group was not a simple historical cohort; it was meticulously constructed through a rigorous, blinded review of the medical charts of 6,867 HSCT patients from participating centers. From this large pool, 32 patients were identified who met the exact same stringent eligibility criteria as the prospectively treated patients, ensuring the groups were as comparable as possible.[6]

The primary endpoint of the study was survival at Day +100 post-HSCT. The results were compelling:

• The observed Day +100 survival rate in the group treated with Defibrotide was 38.2%.
• In the historical control group, the Day +100 survival rate was 25.0%.
• A propensity-adjusted analysis, which accounts for any minor baseline differences between the groups, demonstrated that this difference was statistically significant, with an estimated survival improvement of 23% (95.1% confidence interval [CI], 5.2% to 40.8%; p=0.0109).[6]

A key secondary endpoint, the rate of complete response (CR) by Day +100 (defined as bilirubin <2 mg/dL and resolution of multi-organ failure), was also significantly higher in the Defibrotide group at 25.5% compared to 12.5% in the control group (p=0.0160).[6]

The findings from this pivotal trial were strongly supported by the data from the other two studies. Across all three trials, the Day +100 survival rates for patients with severe VOD/SOS treated with Defibrotide were consistently in the range of 38% to 45%.[4] This survival rate represents a substantial improvement over the expected survival of 21% to 31% for similar patients who receive only supportive care, as determined from analyses of published reports and patient-level historical data.[4]

Table 1: Summary of Pivotal Efficacy Evidence for Defibrotide in VOD/SOS Treatment
Study Identifier	Patient Population (N)	Comparator	Primary Endpoint	Key Result: Day +100 Survival Rate (95% CI)	Key Statistical Finding
Phase 3 Pivotal Trial (NCT00358501)	102	32 Historical Controls	Survival at Day +100 post-HSCT	38.2% (29%, 48%) vs. 25.0% for controls	Propensity-adjusted difference: 23% (p=0.0109) 4
Study 2 (Prospective Trial)	75	Historical Data	Survival at Day +100 post-HSCT	44% (33%, 55%)	Consistent with pivotal trial results 4
Study 3 (Expanded Access)	351	Historical Data	Survival at Day +100 post-HSCT	45% (40%, 51%)	Consistent with pivotal trial results 4

Investigational Uses and Discontinued Trials

Given its efficacy in treating established VOD/SOS, there was strong interest in evaluating Defibrotide for the prevention of the disease in high-risk patients. A large, randomized, open-label Phase 3 study (NCT02851407) was initiated for this purpose.[28] The trial was designed to compare the efficacy of prophylactic Defibrotide plus best supportive care against best supportive care alone in preventing VOD in high-risk adult and pediatric HSCT recipients.

However, in April 2020, the sponsor, Jazz Pharmaceuticals, announced the early termination of enrollment in this study. The decision was based on a recommendation from the study's Independent Data Monitoring Committee (IDMC), which had conducted a pre-planned interim analysis. The IDMC concluded that it was highly unlikely the study would achieve its primary endpoint of VOD-free survival at Day +30 post-HSCT if it were to continue to completion.[30]

The divergent outcomes of the treatment and prevention trials provide critical insight into the specific therapeutic niche of Defibrotide. The failure of the prevention trial suggests that Defibrotide's endothelial-protective effects are insufficient to completely block the initial, overwhelming toxic insult delivered to the hepatic sinusoids by high-dose conditioning chemotherapy. This initial event is the primary driver of VOD pathogenesis. In contrast, the success of the treatment trials indicates that Defibrotide is highly effective at intervening once the disease is established. At this stage, the pathology is characterized by a self-perpetuating cycle of endothelial activation, microthrombosis, impaired fibrinolysis, and inflammation. The known mechanisms of Defibrotide—enhancing plasmin activity, increasing t-PA, decreasing PAI-1, and protecting the remaining viable endothelial cells—are ideally suited to disrupt this secondary, established pathological cascade.[7] Therefore, the evidence suggests that Defibrotide is not a prophylactic shield against the initial chemotherapeutic injury but rather a potent rescue therapy that can reverse the downstream thrombotic and endothelial consequences of that injury.

Safety, Tolerability, and Risk Management

The clinical management of patients receiving Defibrotide requires a thorough understanding of its safety profile, which is dominated by the risk of hemorrhage. Given that the target patient population is already critically ill and coagulopathic, careful monitoring and adherence to risk mitigation strategies are paramount.

Adverse Reactions

The safety profile of Defibrotide has been characterized in clinical trials involving a vulnerable population of post-HSCT patients with severe VOD/SOS and multi-organ failure.

• Most Common Adverse Events: The most frequently reported adverse reactions, occurring with an incidence of 10% or greater, are primarily related to hemodynamic changes and gastrointestinal effects. These include hypotension (abnormally low blood pressure), diarrhea, vomiting, nausea, and epistaxis (nosebleeds).[1]
• Serious Adverse Events:
• Hemorrhage: This is the most significant and potentially life-threatening risk associated with Defibrotide therapy. The drug's profibrinolytic activity may increase the risk of bleeding in VOD patients, who are often already thrombocytopenic and coagulopathic due to their underlying condition and prior treatments.[9] Various types of bleeding have been observed, including pulmonary alveolar hemorrhage, gastrointestinal hemorrhage, hematuria (blood in the urine), and cerebral hemorrhage.[1] It is important to contextualize this risk; in the pivotal Phase 3 trial, the incidence of common hemorrhagic adverse events was found to be similar between the Defibrotide-treated group and the historical control group. For example, pulmonary alveolar hemorrhage occurred in 11.8% of Defibrotide patients versus 15.6% of controls, and gastrointestinal bleeding occurred in 7.8% versus 9.4%, respectively.[6] This suggests that while Defibrotide can contribute to bleeding risk, the severe underlying disease state is a major driver of hemorrhagic complications in this population.
• Hypersensitivity Reactions: Allergic reactions have been reported in less than 2% of patients treated with Defibrotide. These reactions can range from mild manifestations like rash and urticaria (hives) to more severe events such as angioedema (swelling of the deep layers of the skin). At least one case of a severe, life-threatening anaphylactic reaction has been reported in a patient who had previously been exposed to the drug.[1]

Contraindications and Warnings

To manage the risks associated with Defibrotide, there are specific contraindications and warnings that must be strictly observed.

• Contraindications:
• The concomitant administration of Defibrotide with systemic anticoagulant therapies (e.g., heparin, warfarin) or fibrinolytic therapies (e.g., alteplase) is contraindicated due to a markedly increased risk of hemorrhage.[3] This contraindication does not apply to the routine, low-dose anticoagulants used for the maintenance or reopening of central venous catheters.[9]
• Defibrotide is contraindicated in patients with a known history of hypersensitivity or anaphylaxis to the drug or any of its excipients.[12]
• Warnings and Precautions:
• Bleeding Risk Management: Defibrotide should not be initiated in patients who have active, clinically significant bleeding. Throughout the course of therapy, all patients must be monitored closely for any signs of bleeding. If significant bleeding develops, Defibrotide should be withheld or permanently discontinued. Supportive care, including transfusions, should be provided to manage the bleeding event. There is no known reversal agent for the profibrinolytic effects of Defibrotide.[7]
• Management During Invasive Procedures: To minimize the risk of procedural bleeding, the Defibrotide infusion should be discontinued at least 2 hours prior to an invasive procedure. Treatment can be resumed after the procedure, once the risk of procedure-related bleeding is deemed to have resolved.[7]
• Hemodynamic Instability: The administration of Defibrotide is not recommended in patients who are hemodynamically unstable. This is specifically defined as the inability to maintain a stable mean arterial pressure with the support of a single vasopressor agent.[9]

Table 2: Profile of Key Adverse Reactions and Risk Management for Defibrotide
Category	Details
Most Common Adverse Reactions (Incidence ≥10%)	Hypotension, Diarrhea, Vomiting, Nausea, Epistaxis 4
Serious Adverse Reactions (Warnings & Precautions)	Hemorrhage: Including Pulmonary Alveolar, Gastrointestinal, and Cerebral Hemorrhage. Hypersensitivity Reactions: Including Rash, Urticaria, Angioedema, and Anaphylaxis 1
Contraindicated Concomitant Medications	Systemic Anticoagulants (e.g., Heparin, Warfarin), Fibrinolytic Therapies (e.g., Alteplase) 7

Drug-Drug Interactions

• Pharmacodynamic Interactions: The most clinically significant interactions are pharmacodynamic in nature, involving other medications that affect hemostasis. The co-administration of anticoagulants or fibrinolytics is contraindicated.[7] Caution should be exercised when using Defibrotide with other drugs that can affect platelet aggregation, such as nonsteroidal anti-inflammatory drugs (NSAIDs).[1] Drug interaction databases predict an increased risk of bleeding when Defibrotide is combined with a wide range of antithrombotic and antiplatelet agents.[17]
• Pharmacokinetic Interactions: Based on in vitro studies, Defibrotide is unlikely to be involved in clinically significant pharmacokinetic drug-drug interactions. It does not induce or inhibit major cytochrome P450 (CYP) drug-metabolizing enzymes (including CYP1A2, CYP2B6, CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6). Furthermore, it is not a substrate or inhibitor of major drug uptake or efflux transporters such as P-glycoprotein (P-gp), BCRP, OATs, OCTs, or OATPs.[9]

Use in Specific Populations

• Pregnancy and Lactation: There are no adequate and well-controlled studies of Defibrotide in pregnant women. Animal reproduction studies in rats showed that at clinically relevant doses, Defibrotide caused hemolytic abortion. Therefore, Defibrotide should not be used during pregnancy, and women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment.[1] It is not known whether Defibrotide is excreted in human milk.
• Pediatric Use: Defibrotide is indicated for use in pediatric patients over one month of age. The safety and efficacy profiles in the pediatric population are consistent with those observed in adults. The recommended dose is the same as for adults.[1]

Dosage, Administration, and Handling

The safe and effective use of Defibrotide requires strict adherence to the approved guidelines for dosing, preparation, and administration. These procedures are designed to ensure optimal therapeutic effect while minimizing the risk of adverse events.

Recommended Dosing Regimen

• Dose: The recommended dosage of Defibrotide for both adult and pediatric patients is 6.25 mg/kg, administered every 6 hours. This results in a total daily dose of 25 mg/kg.[9]
• Dosing Weight Calculation: A critical aspect of dosing is the use of the patient's baseline body weight. This is defined as the patient's weight measured prior to the initiation of the HSCT preparative (conditioning) regimen.[9] This specification is crucial because patients who develop VOD/SOS often experience significant weight gain due to fluid retention and ascites. Using the post-VOD weight would lead to overdosing and an increased risk of toxicity.

Method of Administration

Defibrotide is for intravenous use only and must be diluted before administration.

• Dilution: The 80 mg/mL concentrate must be diluted with either 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP. The final concentration of the diluted solution should be within the range of 4 mg/mL to 20 mg/mL. The total volume of the infusion should be determined based on the individual patient's weight to allow for a 2-hour infusion duration.[9]
• Infusion: The diluted solution should be administered as a constant intravenous infusion over a 2-hour period. Bolus administration should be avoided, as it may cause side effects such as flushing or a sensation of generalized heat.[9]
• Filtration: It is mandatory to administer the diluted Defibrotide solution through an infusion set equipped with a 0.2 micron in-line filter.[9]
• Line Compatibility and Flushing: The intravenous administration line (either peripheral or central) should be flushed with a compatible solution (5% Dextrose or 0.9% Sodium Chloride) immediately before and after the Defibrotide infusion to ensure the full dose is delivered and to prevent admixture with incompatible drugs.[9]
• Visual Inspection: As with all parenteral drug products, the diluted solution should be inspected visually for particulate matter and discoloration prior to administration. Only clear solutions that are free of visible particles should be used.[9]

Duration of Therapy

• The recommended minimum duration of Defibrotide therapy is 21 days.[9]
• If, after 21 days of treatment, the signs and symptoms of hepatic VOD/SOS have not resolved, therapy should be continued. Treatment can be extended until VOD resolution is achieved, up to a maximum duration of 60 days.[9]

Management of Adverse Events (Dose Adjustments)

The prescribing information provides specific guidance for managing adverse events through dose interruption or discontinuation.

• Management of Significant Bleeding: If a patient develops clinically significant bleeding, the Defibrotide infusion should be discontinued immediately. The underlying cause of the bleeding should be treated, and supportive care should be provided. Once the bleeding has stopped and the patient is hemodynamically stable, resuming treatment at the same dose may be considered. However, if a patient experiences recurrent significant bleeding, Defibrotide should be discontinued permanently and not resumed.[9]
• Management of Severe Hypersensitivity: If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, Defibrotide must be discontinued permanently. The reaction should be treated according to the standard of care, and the patient should be monitored until all symptoms have resolved.[9]

Regulatory Status and Market Authorization

The regulatory history of Defibrotide is a significant example of how regulatory agencies approach the evaluation of therapies for rare and life-threatening diseases with high unmet medical need. Its path to approval in major markets was facilitated by the use of several expedited programs designed to bring promising drugs for serious conditions to patients more quickly.

United States (Food and Drug Administration - FDA)

• Sponsor: The New Drug Application (NDA) for Defibrotide was submitted by Jazz Pharmaceuticals, Inc..[10]
• Approval Date: The FDA approved Defitelio® (defibrotide sodium) on March 30, 2016.[4]
• Regulatory Pathway: The development and review of Defibrotide in the U.S. benefited from several key FDA expedited programs:
• Orphan Drug Designation: This designation was granted in May 2003. It is given to drugs intended to treat rare diseases (affecting fewer than 200,000 people in the U.S.) and provides incentives such as tax credits for clinical trials and extended market exclusivity.[25]
• Fast Track Designation: This program is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.[25]
• Priority Review: This designation was granted upon submission of the NDA, indicating the FDA's intention to take action on the application within six months (compared to the standard ten months). It is reserved for drugs that, if approved, would offer significant improvements in the safety or effectiveness of the treatment of a serious condition.[4]

European Union (European Medicines Agency - EMA)

• Marketing Authorisation Holder: The marketing authorisation in the EU is held by Jazz Pharmaceuticals.[5]
• Approval Date: The European Commission granted a marketing authorisation valid throughout the European Union for Defitelio® on October 18, 2013.[13]
• Regulatory Pathway: The pathway in the EU also involved special designations reflecting the nature of the disease and the available data:
• Orphan Medicine Designation: Defibrotide was designated as an orphan medicine on July 29, 2004, for the treatment of VOD, providing similar incentives to the U.S. designation.[5]
• Authorization under "Exceptional Circumstances": The marketing authorisation was granted under this specific provision. This pathway is used when the applicant can demonstrate that they are unable to provide comprehensive data on the efficacy and safety of the medicinal product under normal conditions of use. This is often because the condition to be treated is extremely rare, and it is not possible to conduct a full clinical trial program. The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that, given the rarity and high mortality of severe VOD, a traditional randomized controlled trial was not feasible. They determined that the benefit-risk balance of Defibrotide was positive based on the available data, including the historically controlled trial.[13]
• Post-Marketing Requirements: As a condition of the "exceptional circumstances" approval, the company was required to provide additional data from ongoing studies to further characterize the drug's safety and efficacy profile, ensuring continued monitoring of its performance in the post-market setting.[13]

Conclusion and Future Directions

Defibrotide occupies a vital and unique position in the therapeutic armamentarium for complications of hematopoietic stem-cell transplantation. It stands as a landmark achievement in the field of orphan drug development, providing the first and only effective, life-saving therapy for severe hepatic veno-occlusive disease with multi-organ failure—a condition that was previously associated with almost certain mortality. Its approval, based on a pragmatic yet rigorous evaluation of data from a historically controlled trial and other supporting studies, has fundamentally altered the prognosis for patients afflicted with this devastating syndrome. The successful navigation of expedited regulatory pathways in both the U.S. and E.U. underscores a flexible and patient-centric approach to drug evaluation when faced with rare diseases of extreme severity. However, the clinical application of Defibrotide is not without its challenges. Its use demands a high level of clinical vigilance to manage a significant and inherent risk of hemorrhage in a patient population that is already medically fragile and predisposed to bleeding complications.

Despite its established clinical role, several critical questions regarding Defibrotide remain unanswered, pointing toward important avenues for future research.

• Elucidation of the Precise Mechanism of Action: The foremost scientific challenge is the full molecular characterization of Defibrotide's mechanism. As a complex mixture of oligonucleotides, it is likely that specific sequences or structural motifs within the mixture are responsible for the majority of its therapeutic activity. Future research using advanced analytical and molecular biology techniques should aim to deconstruct this mixture, identify the active pharmacophores, and elucidate their precise interactions with endothelial cells and components of the coagulation and fibrinolytic systems. Success in this area could pave the way for the development of a second-generation, fully synthetic, and more potent agent with a better-defined and potentially improved safety profile.
• Development of Predictive and Pharmacodynamic Biomarkers: The current lack of a reliable biomarker to monitor Defibrotide's biological activity or to predict patient response is a significant clinical gap. Research focused on identifying biomarkers that reflect endothelial protection, restoration of fibrinolytic activity, or downregulation of inflammatory pathways could be invaluable. Such a biomarker could help optimize dosing regimens, identify patients most likely to benefit, and provide early indications of therapeutic response, allowing for more personalized and effective treatment strategies.
• Exploration of Broader Therapeutic Applications: The unique constellation of endothelial-protective, thrombo-regulatory, and anti-inflammatory properties possessed by Defibrotide suggests a plausible therapeutic rationale in other clinical conditions characterized by systemic endothelial injury, microthrombosis, and inflammation. While the trial for VOD prevention did not succeed, its potential as a treatment for other thrombotic microangiopathies (TMAs), sepsis-induced coagulopathy, or even acute respiratory distress syndrome (ARDS) may warrant investigation. Any such exploration would need to be undertaken with extreme caution, carefully balancing the potential for benefit against the well-established risk of hemorrhage.

In conclusion, Defibrotide is a testament to successful therapeutic innovation in a setting of profound unmet medical need. It has saved lives and established a new standard of care. The future of this unique agent and its derivatives will depend on continued scientific inquiry aimed at unraveling its biological complexities, which may, in turn, unlock its potential to treat a wider range of diseases rooted in endothelial dysfunction.

Works cited

1. Defibrotide - Wikipedia, accessed August 15, 2025, https://en.wikipedia.org/wiki/Defibrotide
2. Defibrotide - PubChem, accessed August 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Defibrotide
3. Defibrotide sodium | Leukemia and Lymphoma Society, accessed August 15, 2025, https://www.lls.org/drug/defibrotide-sodium
4. Defitelio (defibrotide sodium) - FDA, accessed August 15, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/defitelio-defibrotide-sodium
5. Defitelio | European Medicines Agency (EMA), accessed August 15, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio
6. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure | Blood | American Society of Hematology, accessed August 15, 2025, https://ashpublications.org/blood/article/127/13/1656/34776/Phase-3-trial-of-defibrotide-for-the-treatment-of
7. FDA Approves DEFITELIO - American College of Clinical Pharmacology, accessed August 15, 2025, https://accp1.org/Members/ACCP1/5Publications___News/FDA_Approves_DEFITELIO_.aspx
8. Defibrotide (Defitelio) | single-stranded oligonucleotide | CAS 83712-60-1 |anti-inflammatory, antithrombotic, profibrinolytic | InvivoChem, accessed August 15, 2025, https://www.invivochem.com/defibrotide.html
9. DEFITELIO (defibrotide sodium) injection Label - accessdata.fda.gov, accessed August 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208114lbl.pdf
10. Defitelio (defibrotide) FDA Approval History - Drugs.com, accessed August 15, 2025, https://www.drugs.com/history/defitelio.html
11. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure - PubMed, accessed August 15, 2025, https://pubmed.ncbi.nlm.nih.gov/26825712/
12. Adult AML Patient - Defitelio® (defibrotide sodium), accessed August 15, 2025, https://www.defitelio.com/defitelio-resources/patient-1
13. Defitelio (defibrotide) - EMA - European Union, accessed August 15, 2025, https://www.ema.europa.eu/en/documents/overview/defitelio-epar-medicine-overview_en.pdf
14. Defibrotide - brand name list from Drugs.com, accessed August 15, 2025, https://www.drugs.com/ingredient/defibrotide.html
15. defibrotide | 83712-60-1 - ChemicalBook, accessed August 15, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51358215.htm
16. [Table, CHEMICAL FORMULA AND STRUCTURE]. - LiverTox - NCBI Bookshelf, accessed August 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548496/table/Defibrotide.T1/
17. Defibrotide: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 15, 2025, https://go.drugbank.com/drugs/DB04932
18. DEFIBROTIDE SODIUM, accessed August 15, 2025, https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/defibrotide-sodium.pdf
19. defibrotide - Drug Central, accessed August 15, 2025, https://drugcentral.org/drugcard/5092
20. Defibrotide sodium|CAS 83712-60-1 - DC Chemicals, accessed August 15, 2025, https://www.dcchemicals.com/product_show-defibrotide-sodium.html
21. Defitelio 80 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) | 4999, accessed August 15, 2025, https://www.medicines.org.uk/emc/product/4999/smpc
22. Defibrotide (Cas 83712-60-1) - Parchem, accessed August 15, 2025, https://parchem.com/chemical-supplier-distributor/defibrotide-018663
23. Defibrotide - LiverTox - NCBI Bookshelf, accessed August 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548496/
24. FDA Approves Defibrotide for Patients who Develop Hepatic Veno-Occlusive Disease After Transplant | ASH Clinical News | American Society of Hematology, accessed August 15, 2025, https://ashpublications.org/ashclinicalnews/news/2886/FDA-Approves-Defibrotide-for-Patients-who-Develop
25. Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD - Investors, accessed August 15, 2025, https://investor.jazzpharma.com/news-releases/news-release-details/results-phase-3-trial-defibrotide-treatment-severe-veno/
26. Defitelio® (defibrotide sodium) | VOD/SOS, accessed August 15, 2025, https://defitelio.com/
27. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients | ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT00358501
28. Defibrotide Completed Phase 3 Trials for Veno-Occlusive Disease Prevention - DrugBank, accessed August 15, 2025, https://go.drugbank.com/drugs/DB04932/clinical_trials?conditions=DBCOND0028865&phase=3&purpose=prevention&status=completed
29. A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant | Dana-Farber Cancer Institute, accessed August 15, 2025, https://www.dana-farber.org/clinical-trials/17-654
30. Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease, accessed August 15, 2025, https://investor.jazzpharma.com/node/17011/pdf
31. Defibrotide Uses, Side Effects & Warnings - Drugs.com, accessed August 15, 2025, https://www.drugs.com/mtm/defibrotide.html